SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-177619
Filing Date
2022-06-21
Accepted
2022-06-21 16:01:59
Documents
12
Period of Report
2022-06-17
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d362597d8k.htm   iXBRL 8-K 28803
  Complete submission text file 0001193125-22-177619.txt   154114

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tsha-20220617.xsd EX-101.SCH 2852
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20220617_lab.xml EX-101.LAB 18739
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20220617_pre.xml EX-101.PRE 11705
6 EXTRACTED XBRL INSTANCE DOCUMENT d362597d8k_htm.xml XML 3468
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 221028092
SIC: 2836 Biological Products, (No Diagnostic Substances)